

Maryland Cannalytics, LLC  
57 Aileron CT, Suite 15  
Westminster, MD 21157



New Jersey Cannalytics, LLC  
299 Rdgedale Ave., Unit 1A  
East Hanover, NJ 07936

US Cannalytics, LLC  
3535 High Point Blvd, Suite 400  
Bethlehem, PA 18017

Florida Cannalytics, LLC  
2251 Consulate Dr., Suite 150-160  
Orlando, FL 32837

Michigan Cannalytics, LLC  
21445 Hoover Rd., Suite 222A  
Warren, MI 48089

Friday, March 27, 2026

Chairwoman Pamela Beidle  
Finance Committee  
Miller Senate Office Building, 3 East Wing  
11 Bladen St., Annapolis, MD 21401-1991

**RE: Letter of Support for SB 1008 Alcohol and Cannabis – Cannabinoid Beverages Off-Premises Sales Permit – Establishment**

Dear Chairwoman Beidle & Committee Members,

My name is Karrissa M. Miller, a Maryland MSW licensed social worker, and founding partner in one of the nation's largest privately owned, multi-state cannabis testing laboratories, US Cannalytics. I am currently serving as the organization's Vice President of Quality, Regulatory & Government Affairs, with direct oversight of the quality and compliance safety testing performed at our Westminster, MD facility, Maryland Cannalytics LLC (MD Cannalytics), registered under the former Maryland Medical Cannabis Commission (MMCC) in 2018, with continued service to the Maryland market under the current Maryland Cannabis Administration (MCA). **To date, MD Cannalytics is honored to have tested over 75,000 unique lots of Maryland medical and/or adult-use cannabis or cannabis products on behalf of cannabis consumers and submit this Letter of Support for SB 1008.**

SB 1008 would allow licensed alcohol retailers with off-site sales privileges to sell cannabinoid beverages containing up to 5mg of tetrahydrocannabinol (THC), the primary intoxicant in cannabis. While these products currently exist in Maryland's legal cannabis market, at up to 10mg per serving, SB 1008 would allow for a low-dose cannabis experience, in a highly dilute form, expected to range between 0.0013-0.0015% by weight, when packaged in a standard 12oz can.

Under SB 1008, all beverages, regardless of their formulation and intended final route of distribution would be required to be formulated with legally cultivated Maryland cannabis, extracted and manufactured in licensed cannabis processing facilities, packaged in a manner compliant with existing labeling requirements for safe identification and consumption of cannabis and tested by independent testing laboratories registered under the MCA. In short, these products would both reflect the same child-safe packaging, safety testing and labeling requirements, supporting informed adult-use cannabis consumption, while safeguarding reasonable consumer protections for this product type.

Maryland Cannalytics, LLC  
57 Aileron CT, Suite 15  
Westminster, MD 21157



New Jersey Cannalytics, LLC  
299 Rdgedale Ave., Unit 1A  
East Hanover, NJ 07936

US Cannalytics, LLC  
3535 High Point Blvd, Suite 400  
Bethlehem, PA 18017

Florida Cannalytics, LLC  
2251 Consulate Dr., Suite 150-160  
Orlando, FL 32837

Michigan Cannalytics, LLC  
21445 Hoover Rd., Suite 222A  
Warren, MI 48089

---

**As a multi-state cannabis testing laboratory, we believe SB 1008 also proactively addresses the infiltration of illicit and/or unsafe cannabis beverages into our state, which are currently available in neighboring states, such as Delaware and New Jersey, and do not require in-state manufacturing, testing, nor labeling under the existing state-specific cannabis regulatory bodies,**

These mass-produced, out-of-state and unregulated products available for legal purchase in Delaware and New Jersey's liquor stores, present great risks to consumers, as they only require a federally compliant THC test for hemp derived products, without the contaminate testing needed to ensure harmful residual solvents, such as toluene and hydrochloric acid, used to convert hemp-derived CBD to THC, are appropriately purged from the product, prior to sale, and are not required to be safely and accurately labeled with pre-defined acceptance criteria. Additionally, based on consumer-testing performed across our organization, we believe these products are often formulated well below the expected dosage advertised on the can, potentially misrepresenting or misleading consumers at the time of purchase.

**This letter of support for SB 1008 comes on behalf of our multi-state cannabis testing organization, and me, as a public health advocate and educator within the cannabis market.** Outside of my organization, I am honored to facilitate several independent, market-leading public health and consumer safety roles, such as my appointment to the Maryland Cannabis Public Health Advisory Council, under the Moore-Miller Administration in 2023.

**With SB 1008, Maryland can define a nation-wide model for safe-entry for these low-dose products to licensed alcohol retailers with off-site sales privileges, by granting a transparent process, utilizing our existing cannabis cultivation, manufacturing and testing infrastructure, to ensure reasonable consumer safety protections under the existing safety testing, labeling and child-safe packaging requirements.**

Respectfully,

Karrissa M. Miller, LMSW

Founding Partner & Vice President of Quality, Regulatory & Government Affairs, US Cannalytics,  
Operating as Maryland Cannalytics, LLC in Westminster, MD  
Vice Chair, Maryland Cannabis Public Health Advisory Council  
Vice Chair, New Jersey Cannabis Business Association (NJCBA), Laboratory Testing Committee